Optimización y análisis crítico del estudio de la monotorización de enfermedad mínima residual mediante ASO RQ:PCR en pacientes con mieloma múltiple. Comparación con la citometría de flujo
type: CreativeWork
description: [EN] In patients with multiple myeloma ( MM) , the quality of response to treatment has been shown to have prognostic value , so that today the complete response (CR ) represents a therapeutic target in all MM schemes . However, we know that the current response criteria are suboptimal , since they are based on low sensitivity techniques such as immunofixation and morphology. Several studies indicate that immunophenotypic and molecular techniques are more sensitive and allow assessing minimal residual disease (MRD ) in bone marrow (BM ) , so that a better quality of response would be associated with longer survival. In the molecular field , strategies based on the use of specific primers and probes to quantify a patient and the tumor mass (ASO RQ- PCR ) has shown clinical value in patients with MM . Since the applicability of the same low, we consider first objective of this thesis improve its applicability , the search for new molecular markers and / or the use of samples enriched in plasma cells by CD138 + selection . Of molecular markers used in MM , VDJH somatic mutations frequently occurs and is detected only DJH in 60 % of patients . Alternatively, the Kappa deleting element rearrangements ( Kde ) are detected in all lymphoproliferative lambda B and 1/3 of the kappa and somatic mutations have not compromise the efficiency of primers and probes . Therefore, as in acute lymphoblastic leukemia , may be successfully used as markers for EMR in MM . This rearrangement studied in 96 patients with MM and found that is detected in 50 % of them , which can be easily sequenced and no somatic mutations. Then analyze its value as an additional marker in MM and saw EMR increases the applicability of these studies in 9% of cases overall and in 20 % of cases of MM lambda group that would be a significant advance . Then investigated using samples enriched MO plasma cells by immunomagnetic selection CD138 + as a material for obtaining molecular markers of EMR by PCR in MM . For…
abstract: [EN] In patients with multiple myeloma ( MM) , the quality of response to treatment has been shown to have prognostic value , so that today the complete response (CR ) represents a therapeutic target in all MM schemes . However, we know that the current response criteria are suboptimal , since they are based on low sensitivity techniques such as immunofixation and morphology. Several studies indicate that immunophenotypic and molecular techniques are more sensitive and allow assessing minimal residual disease (MRD ) in bone marrow (BM ) , so that a better quality of response would be associated with longer survival. In the molecular field , strategies based on the use of specific primers and probes to quantify a patient and the tumor mass (ASO RQ- PCR ) has shown clinical value in patients with MM . Since the applicability of the same low, we consider first objective of this thesis improve its applicability , the search for new molecular markers and / or the use of samples enriched in plasma cells by CD138 + selection . Of molecular markers used in MM , VDJH somatic mutations frequently occurs and is detected only DJH in 60 % of patients . Alternatively, the Kappa deleting element rearrangements ( Kde ) are detected in all lymphoproliferative lambda B and 1/3 of the kappa and somatic mutations have not compromise the efficiency of primers and probes . Therefore, as in acute lymphoblastic leukemia , may be successfully used as markers for EMR in MM . This rearrangement studied in 96 patients with MM and found that is detected in 50 % of them , which can be easily sequenced and no somatic mutations. Then analyze its value as an additional marker in MM and saw EMR increases the applicability of these studies in 9% of cases overall and in 20 % of cases of MM lambda group that would be a significant advance . Then investigated using samples enriched MO plasma cells by immunomagnetic selection CD138 + as a material for obtaining molecular markers of EMR by PCR in MM . For…
author: Puig Morón, Noemí
keywords: Tesis y disertaciones académicas, Universidad de Salamanca (España), Tesis Doctoral, Academic dissertations, Hematología, Hematopatología, Hematology, Hematopathology
date published: 2013
date modified: 2026-07-27T21:03:17Z
provider: Universidad de Salamanca
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: Universidad de Salamanca